Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-10T23:04:42.132Z Has data issue: false hasContentIssue false

In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection

Published online by Cambridge University Press:  01 April 2000

JUN WANG
Affiliation:
Program in Infectious Diseases and Immunity, University of California, Berkeley, California 94720, USA
HONG JIANG
Affiliation:
Program in Infectious Diseases and Immunity, University of California, Berkeley, California 94720, USA
FENYONG LIU
Affiliation:
Program in Infectious Diseases and Immunity, University of California, Berkeley, California 94720, USA Program in Comparative Biochemistry, University of California, Berkeley, California 94720, USA
Get access

Abstract

Ribonuclease-resistant RNA molecules that bind to infectious human cytomegalovirus (HCMV) were isolated in vitro from a pool of randomized sequences after 16 cycles of selection and amplification. The two ligands (L13 and L19) characterized exhibited high HCMV-binding affinity in vitro and effectively inhibited viral infection in tissue culture. Their antiviral activity was also specific as they only reacted with two different strains of HCMV but not with the related herpes simplex virus 1 and human cells. These two ligands appeared to function as antivirals by blocking viral entry. Ultraviolet (UV) crosslinking studies suggested that L13 and L19 bind to HCMV essential glycoproteins B and H, respectively. Thus, RNA ligands that bind to different surface antigens of HCMV can be simultaneously isolated by the selection procedure. Our study demonstrates the feasibility of using these RNA ligands as a research tool to identify viral proteins required for infectivity and as an antiviral agent to block viral infection.

Type
Research Article
Copyright
© 2000 RNA Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)